Takeda Pharmaceuticals Company Limited (Takeda) announced that the company will invest more than US$106.35 million (£100 Million) to build Dengue vaccine Manufacturing Plant in Singen, Germany.
Takeda plans to meet unmet needs in dengue prevention through Dengue Vaccine Candidate (TAK-003).
TAK-003 is Takeda’s tetravalent dengue vaccine candidate, which is based on a live-attenuated dengue serotype 2 viruses (DENV-2). It provides genetic backbone for all four vaccine viruses.
To support the protection of populations and individuals who suffer from dengue virus, Takeda develops dengue vaccine. Investment on this manufacturing plant strengthens Takeda’s strong support for global vaccine strategy in general, and dengue in particular.
Unmet medical needs can be reduced and this Dengue Vaccine Manufacturing Plant will provide millions of people with access to a medicine.
Currently there are five different kinds of dengue vaccine candidates that are undergoing clinical trials, including live-attenuated vaccines, subunit, DNA and purified inactivated vaccine candidates.
|Takeda Pharmaceuticals Company Limited (Takeda)
|US$106.35 million (£100 Million)